1 week Ago By Defense World Staff
Corebridge Financial Inc. lessened its stake in Cogent Biosciences, Inc. ( NASDAQ:COGT – Free Report ) by 7.
0% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 45,621 shares of the technology company’s stock after selling 3,443 shares during the quarter. Corebridge Financial Inc.
’s holdings in Cogent Biosciences were worth $356,000 at the end of the most recent quarter. Other institutional investors have also recently added to or reduced their stakes in the company. Vanguard Group Inc.
raised its position in Cogent Biosciences by 7.3% in the fourth quarter. Vanguard Group Inc.
now owns 6,133,380 shares of the technology company’s stock valued at $47,840,000 after purchasing an additional 418,975 shares during the period. KLP Kapitalforvaltning AS acquired a new stake in Cogent Biosciences in the fourth quarter valued at $88,000. Quantbot Technologies LP bought a new position in shares of Cogent Biosciences during the fourth quarter worth about $169,000.
Teacher Retirement System of Texas grew its position in shares of Cogent Biosciences by 15.4% in the 4th quarter. Teacher Retirement System of Texas now owns 17,983 shares of the technology company’s stock worth $140,000 after acquiring an additional 2,396 shares in the last quarter.
Finally, Intech Investment Management LLC increased its stake in Cogent Biosciences by 99.3% during the fourth quarter. Intech Investment Management LLC now owns 56,657 shares of the technology company’s stock valued at $442,000 after purchasing an additional 28,233 shares during the last quarter.
Analysts Set New Price Targets A number of analysts have recently weighed in on the company. HC Wainwright dropped their price target on Cogent Biosciences from $17.00 to $14.
00 and set a “buy” rating on the stock in a research report on Tuesday, January 14th. Piper Sandler raised Cogent Biosciences to a “strong-buy” rating in a report on Friday, March 7th. Robert W.
Baird lowered their price objective on shares of Cogent Biosciences from $10.00 to $8.00 and set a “neutral” rating on the stock in a research note on Thursday, February 27th.
Needham & Company LLC reaffirmed a “hold” rating on shares of Cogent Biosciences in a report on Wednesday, February 26th. Finally, Scotiabank assumed coverage on Cogent Biosciences in a report on Friday, March 7th. They issued a “sector outperform” rating and a $17.
00 target price for the company. Three analysts have rated the stock with a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $14.
43. Cogent Biosciences Stock Performance Cogent Biosciences stock opened at $4.46 on Thursday.
The stock has a 50-day simple moving average of $7.11 and a 200 day simple moving average of $8.72.
The stock has a market capitalization of $507.77 million, a P/E ratio of -1.80 and a beta of 1.
67. Cogent Biosciences, Inc. has a 52 week low of $3.
72 and a 52 week high of $12.61. Cogent Biosciences Company Profile ( Free Report ) Cogent Biosciences, Inc, a biotechnology company, focuses on developing precision therapies for genetically defined diseases.
Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. Read More Five stocks we like better than Cogent Biosciences 3 Must-Buy Warren Buffett Stocks for Volatile Times Quantum Computing: The $6.5 Billion Opportunity You Can’t Ignore Are Penny Stocks a Good Fit for Your Portfolio? Are Tariffs Threatening Disney’s Comeback Story? What is diluted earnings per share (Diluted EPS)? Is Alphabet a Generational Buying Opportunity at These Levels? Receive News & Ratings for Cogent Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cogent Biosciences and related companies with MarketBeat.
com's FREE daily email newsletter ..
